Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11N

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11N

The cholecystokinin-2 receptor (CCK2R) is an attractive target in nuclear medicine due to its overexpression by different tumors. Several radiolabeled peptidic ligands targeting the CCK2R have been investigated in the past; however, their low stability against proteases can limit their uptake in tum...

Full description

Bibliographic Details
Main Authors:	Nathalie M. Grob, Roger Schibli, Martin Béhé, Thomas L. Mindt
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Cancers
Subjects:	cholecystokinin-2 receptor peptidomimetics minigastrin molecular imaging peptide receptor radionuclide therapy
Online Access:	https://www.mdpi.com/2072-6694/13/11/2629

Similar Items

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [<sup>177</sup>Lu]Lu-PP-F11N
by: Michal Grzmil, et al.
Published: (2021-12-01)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [<sup>225</sup>Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
by: Yun Qin, et al.
Published: (2020-11-01)

Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs
by: Nadine Holzleitner, et al.
Published: (2023-07-01)

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs
by: Taraneh Sadat Zavvar, et al.
Published: (2023-02-01)

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs
by: Nadine Holzleitner, et al.
Published: (2024-03-01)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

Development of the First <sup>18</sup>F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety
by: Thomas Günther, et al.
Published: (2023-03-01)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
by: Anton Amadeus Hörmann, et al.
Published: (2020-10-01)

Automated Synthesis of <sup>68</sup>Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
by: Anton Amadeus Hörmann, et al.
Published: (2022-03-01)

Radiopharmaceutical Formulation and Preclinical Testing of <sup>68</sup>Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
by: Anton A. Hörmann, et al.
Published: (2021-06-01)

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study
by: Christof Rottenburger, et al.
Published: (2024-04-01)

Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo
by: Nadine Holzleitner, et al.
Published: (2022-11-01)

Amino Acid Solutions for <sup>177</sup>Lu-Oxodotreotide Premedication: A Tolerance Study
by: Pierre Courault, et al.
Published: (2022-10-01)

Lutathera<sup>®</sup> Orphans: State of the Art and Future Application of Radioligand Therapy with <sup>177</sup>Lu-DOTATATE
by: Luca Urso, et al.
Published: (2023-03-01)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor Patients
by: Morticia N. Becx, et al.
Published: (2022-11-01)

Glucose Metabolism Modification Induced by Radioligand Therapy with [<sup>177</sup>Lu]Lu/[<sup>90</sup>Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
by: Luca Urso, et al.
Published: (2022-09-01)

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
by: Anna Stenvall, et al.
Published: (2022-12-01)

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [<sup>177</sup>Lu]Lu-Satoreotide Tetraxetan and the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST<sub>2</sub>-Positive Tumours
by: Pascale Plas, et al.
Published: (2022-08-01)

Efficacy of <sup>177</sup>Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study
by: Golmehr Sistani, et al.
Published: (2020-12-01)

Simultaneous Visualization of <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
by: Francesca Borgna, et al.
Published: (2021-04-01)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023-05-01)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of <sup>177</sup>Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
by: Rashmi G. Shah, et al.
Published: (2021-01-01)

Correlations between [<sup>68</sup>Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Ragnar Bruvoll, et al.
Published: (2023-02-01)

Novel NK1R-Targeted <sup>68</sup>Ga-/<sup>177</sup>Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships
by: Joanna Matalińska, et al.
Published: (2022-01-01)

In Vitro Biological Evaluation of Aprepitant Based <sup>177</sup>Lu-Radioconjugates
by: Paweł K. Halik, et al.
Published: (2022-03-01)

Dosimetric Evaluation of <sup>177</sup>Lu Peptide Receptor Radionuclide Therapy Using GATE and Planet Dose
by: Ioanna Stamouli, et al.
Published: (2023-08-01)

Combination of [<sup>177</sup>Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
by: Marina Simón, et al.
Published: (2022-06-01)

Anatomy-based correction of kidney PVE on $$^{177}\text{Lu}$$ 177 Lu SPECT images
by: Julien Salvadori, et al.
Published: (2024-02-01)

Synthesis, Characterization, and Therapeutic Efficacy of <sup>177</sup>Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors
by: Dragana Stanković, et al.
Published: (2023-07-01)

Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE
by: Wendy Delbart, et al.
Published: (2023-04-01)

Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE
by: Amir Sabet, et al.
Published: (2021-10-01)

Mechanism of Action and Structure–Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor
by: Daniela G. Dengler, et al.
Published: (2023-01-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

Long-Term Survival and Value of <sup>18</sup>F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with <sup>177</sup>Lu-DOTATATE
by: Margarida Rodrigues, et al.
Published: (2021-03-01)

Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery
by: Yeon Sun Lee
Published: (2022-09-01)

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATE
by: Rosalba Mansi, et al.
Published: (2021-12-01)

p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
by: Sara Lundsten, et al.
Published: (2021-11-01)

Evaluation of a New <sup>177</sup>Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5
by: Rosalba Mansi, et al.
Published: (2020-09-01)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01)

QSAR Modelling of Peptidomimetic Derivatives towards HKU4-CoV 3CL<sup>pro</sup> Inhibitors against MERS-CoV
by: Imad Hammoudan, et al.
Published: (2021-03-01)